SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Epic Bio, a leading epigenetic editing company that plans to have its FSHD program enter the clinic this year, today announced that Amber Salzman, Ph.D., chief executive officer, participated in a fireside chat at the Canaccord Genuity - Genetic Medicine for Generalists Fireside Chat today.

加利福尼亚州南旧金山，2024年4月10日（环球通讯社）--Epic Bio是一家领先的表观遗传编辑公司，计划今年将其FSHD项目引入诊所，今天宣布首席执行官Amber Salzman博士参加了Canaccord Genuity-Genetic Medicine for Generalists fireside chat的炉边聊天。

Institutional investors should contact their Canaccord representatives for additional information or to view the replay. About Epic BioEpic Bio is a leading epigenetic editing company, leveraging the power of CRISPR without cutting DNA. The company’s proprietary Gene Expression Modulation System (GEMS) includes the smallest Cas protein known to work in human cells, enabling in vivo or ex vivo delivery via a single viral vector.

机构投资者应联系其Canaccord代表以获取更多信息或查看重播。关于Epic BioPic Bio是一家领先的表观遗传编辑公司，利用CRISPR的功能而不切割DNA。该公司专有的基因表达调控系统（GEMS）包括已知在人类细胞中起作用的最小Cas蛋白，可通过单一病毒载体进行体内或离体递送。

Epic plans to begin dosing patients in a clinical trial of its lead program — EPI-321 for the treatment of facioscapulohumeral muscular dystrophy (FSHD) — in 2024; additional programs seek to address alpha-1 antitrypsin deficiency (A1AD), heterozygous familial hypercholesterolemia (HeFH), and other indications.

Epic计划于2024年开始在其主要项目EPI-321治疗面肩肱型肌营养不良症（FSHD）的临床试验中给患者服用药物；其他计划寻求解决α-1抗胰蛋白酶缺乏症（A1AD），杂合性家族性高胆固醇血症（HeFH）和其他适应症。

Visit www.epic-bio.com for more information or follow us on Twitter and LinkedIn.  Investor Contact Shawn M. CoxEpic BioManager, Investor Relations, and Corporate Communicationsshawn.cox@epic-bio.com Media Contact Lisa RaffenspergerTen Bridge Communicationslisa@tenbridgecommunications.com(617) 903-8783 .

有关更多信息，请访问www.epic-bio.com，或在Twitter和LinkedIn上关注我们。投资者联系人Shawn M.CoxEpic BioManager，投资者关系和公司Communicationsshawn.cox@epic-bio.com媒体联系人Lisa RaffenspergerTen BridgeCommunicationslisa@tenbridgecommunications.com（617）903-8783。